 | |
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| UNII | |
| Chemical and physical data | |
| Formula | C5H7NO4S |
| Molar mass | 177.17 g·mol−1 |
| 3D model (JSmol) | |
| |
Cimlanod (development codes CXL-1427 and BMS-986231) is an experimental drug for the treatment of acute decompensated heart failure. It was discovered by Cardioxyl Pharmaceuticals, which was acquired by Bristol-Myers Squibb. It is a nitroxyl donor.
Cimlanod is a prodrug of CXL-1020.
A preliminary study showed efficacy in patients with class III and IV heart failure. A phase II clinical trial was completed in 2016.